Apoptosis is an essential physiological process that regulates cellular proliferation. Here, we explored the effect of DNA sequence variation within the BCL-2 gene on prostate cancer susceptibility in three clinical populations, consisting of 428 African Americans, 214 Jamaicans and 218 European Americans. We observed a 70% reduced risk for prostate cancer among the European Americans who had possessed two copies of a promoter variant À938C/A. Additionally, common BCL-2 haplotypes appeared to influence prostate cancer risk; however, studies in larger data sets are needed to confirm our findings. Our data suggest that inherited BCL-2 variants may be associated with a decrease in prostate cancer susceptibility.
Introduction
Prostate cancer is the leading cancer and the second leading cause of cancer-related deaths among men in the United States. 1 In 2005, the American Cancer Society estimates that approximately 232 090 male residents in the US will be diagnosed with prostate cancer and 30 350 will die from the disease. Prostate cancer accounts for approximately 33 and 10% of all new cancer-related cases and deaths among men in the US, respectively. Interestingly, African Americans are approximately 1.6-fold more likely to be diagnosed with prostate cancer when compared to men of European descent. 1 Moreover, male residents of Kingston, Jamaica were reported to have a higher incidence of prostate cancer than African Americans (242.3-378.1 new cases/100 000 vs 147.5-249.1) during the 1983-1993 time period. 2 Reasons for the relatively high risk of developing prostate cancer among men of African descent are unclear, but may be partially attributed to differences in prostate cancer-screening practices, dietary habits, environmental exposures and imbalances in selected biological/pathological pathways, such as apoptosis or programmed cell death.
Apoptosis is an essential physiological process that regulates homeostasis of cellular proliferation, maturation of the immune system, oncogenesis and tumour progression. 3 Apoptosis results in the removal of damaged, infected and genetically altered or transformed cells and is characterized by DNA fragmentation and loss of mitochondrial function, including electron transport, ATP production and activation of caspases or proapoptotic proteases. 4 Apoptotic signalling is driven through different pathways involving a series of proteins that may act synergistically with several enzyme cascades. Several proteins activate apoptosis, such as bax, bak and bad, whereas others block this pathway, including mcl-1, bcl-xl and bcl-2. 5 Both proapoptotic and antiapoptotic bcl-2 subfamilies share evolutionarily conserved sequences known as bcl-2 homology (BH) at certain domains (i.e., BH1, BH2, BH3 and BH4). In terms of proapoptotic proteins, the Bax family proteins consist of two subfamilies that contain either two or three BH domains or a BH3-only domain (e.g., bid, bad and bim), suggesting that the BH3 domain is necessary and sufficient for their prodeath action. 4, [6] [7] [8] The prosurvival (antiapoptotic) subfamily contains at least three BH domains, but usually have all four (BH1-4) domains. The hydrophobic groove formed by the BH1-3 domains of the antiapoptotic proteins can dimerize with the BH3 domain of proapoptotic proteins and potentially antagonize their prosurvival activity. 6, [9] [10] [11] [12] A balance between prosurvival and prodeath regulators of apoptosis is critical in the maintenance of tissue homeostasis. It is now believed that clonal expansion and tumour growth result from increased cell proliferation and decreased apoptotic cell death. Failure to undergo apoptosis may enable survival of transformed cells that are prone to undergo further genetic alteration and show genomic instability, leading to the invasive phenotype. 13, 14 Either downregulation of proapoptotic or upregulation of antiapoptotic activity may promote tumour survival.
Few investigators have examined the relationship between bcl-2 protein expression and the pathogenesis of prostate cancer. For instance, upregulation of the bcl-2 antiapoptotic protein has been implicated in the pathogenesis of haematologic and epithelial malignancies, including carcinomas of the lung, colon, breast and prostate. 15 Moreover, higher bcl-2 immunostaining was associated with more advanced prostate cancer, (i.e., higher Gleason grade), suggesting that an increase in this antiapoptotic protein may occur during the progression of prostate cancer. [16] [17] [18] [19] Lastly, Mc Conkey et al. 20 demonstrated an increased expression level of bcl-2 and loss of bax (proapoptotic) expression in prostatic carcinoma cells. Based on these studies, we hypothesized that genetic alteration in antiapoptotic genes, including BCL-2, may play an important role in the pathogenesis of prostate cancer, presumably owing to an accumulation of genetically altered and transformed cells.
The polymorphic BCL-2 gene is unusually large (B200 kb), consisting of three exons and two promoters (i.e., P1 and P2) that regulate bcl-2 transcriptional control, as depicted in Figure 1 . 21 Based on findings from site-directed mutagenesis assays, the P1 and P2 regions contain a plethora of trans-acting sites that play a role in the up-or downregulation of bcl-2 transcription, including negative regulators of P1 (WT1 binding site), positive regulators of P1 (WT1, c-AMP response elements (CRE) and Sp1 sites) and positive regulators of P2 (Cdx sites) activity. 21 Additionally, sequences within the BCL-2 promoter region of exon 3 are essential for the antiapoptotic activity of its corresponding gene product. 21 However, very little is known about the role genetic alterations within the non-coding and coding regions of the BCL-2 gene play in cancer susceptibility.
To our knowledge, there are no reported findings on the relationship between genetic variations within the BCL-2 gene and prostate cancer susceptibility. Thus, the main objective of this study was to assess the relationship between polymorphic BCL-2 and the risk of developing prostate cancer among men of African and European descent. In addition, we constructed BCL-2 haplotypes to determine whether these sequence variations co-segregate with prostate cancer in either subpopulation. We hypothesize that genetic variations within the transcription regulatory and translation regions of the BCL-2 gene may alter bcl-2 mRNA/protein levels, resulting in imbalances in cell death or survival, and ultimately to altered prostate cancer risk. The use of high-throughput molecular genotyping methodologies alone and/or combined with available information on transcription factor binding sites will help to establish associations between genetic variations within the transcriptional regulatory and coding regions of the BCL-2 gene and the risk of developing prostate cancer. It is our hope that novel or previously identified singlenucleotide polymorphisms (SNPs) within the BCL-2 gene may help explain disparities in the risk of developing prostate cancer between men of African and European descent and provide clues on the therapeutic regimens to treat prostate cancer and its progression.
Materials and methods

Subjects
Unrelated men (n ¼ 860) who had available whole blood were enrolled in a case-control study on the genetic risk factors of prostate cancer, involving two sites within the United States and one international site, as detailed in Table 1 . All prostate cancer cases were between 40 and 85 years of age and were diagnosed with prostate cancer within a year before recruitment. All unaffected men had prostate-specific antigen (PSA) levels o4.0 ng/ml and normal digital rectal exams.
The first group of study participants consisted of 428 African-American men (131 prostate cancer patients and 297 male controls) recruited from the Washington, DC area through the Division of Urology at Howard University Hospital and/or the prostate cancer-screening program at the Howard University Cancer Center. All prostate cancer cases and healthy controls were accrued during the same time frame between the years 2000 and 2003. Unaffected African-American male volunteers were enrolled among individuals undergoing regular physical exams at the Division of Urology at Howard University Hospital and/or men participating in the prostate cancer-screening program at the Howard University Cancer Center. The screening program was demographically similar to the patient population seen in the Division of Urology at Howard University Hospital.
The second sub-population consisted of 214 men of African descent, who resided on the Caribbean island of Jamaica (88 prostate cancer cases and 126 age-matched controls). Jamaican men were recruited during the year of 2000 from the University Hospital of the West Indies in Kingston, Jamaica. Each case subject was diagnosed with prostate carcinoma by a pathologist. Men free of prostate Figure 1 The BCL-2 gene (B200 kb) consists of three exons and two promoters, namely P1 and P2 that mediate transcriptional control. In the current study, we detected three SNPs within the non-coding region (À938C/A, À758Tins and À42C/T) upstream of the mRNA start site and one SNP within the coding region of exon 2 ( þ 21A/ G). The shaded areas represent coding regions and the white areas are non-coding regions. This figure was adapted from Lang et al.
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cancer were recruited from prostate cancer-screening programs on the island as well.
Lastly, 218 European-American men (93 prostate cancer patients and 125 unaffected male controls) were recruited through various prostate cancer-screening programs in Baltimore, MD, sponsored by the Brady Urological Institute at Johns Hopkins.
Blood samples were collected from all study participants from the three aforementioned clinical sites. Clinical characteristics including Gleason grade, PSA and age at diagnosis were obtained from medical records. Individuals diagnosed with benign prostatic hyperplasia were not considered in this analysis. The Institutional Review Boards at Howard University approved the study and written consent was obtained from all subjects.
BCL-2 SNP discovery
Genomic DNA was isolated from lymphocytes using standard proteinase K digestion, cell lysis, protein precipitation and DNA precipitation. A total of 1500 bp upstream of the ATG start site of exon 1 and the two coding exons of the BCL-2 gene (Genebank accession number NT_025028 for the DNA sequence and NM_000633 for the RNA sequence) were screened for DNA sequence variation by denaturing high-performance liquid chromatography (dHPLC). Information about the primers and polymerase chain reaction (PCR) conditions used to amplify the BCL-2 promoter and exon fragments are detailed in Table 2 . Genomic DNA collected from 48 African-American individuals (24 cases and 24 controls) was used for SNP detection. Following PCR, the samples were heated at 951C for 4-8 min, and cooled at room temperature for 20 min. The samples were then loaded into the dHPLC instrument (WAVE DNA Fragment Analysis System, Transgenomics, Omaha, NE, USA) and run with an initial gradient of 45% buffer A (0.1 M triethylammonium acetate (TEAA) solution, pH 7.0) and 55% buffer B (0.1 M TEAA containing 25% acetonitrile, pH 7.0), followed by a final gradient of 36% buffer A and 64% buffer B, using an acquisition time of 8.7 min. All samples demonstrating heteroduplex peaks were sequenced in both directions using an ABI 377 DNA sequencer (ABI, Foster City, CA, USA) to confirm the presence of SNPs and to identify any polymorphisms within the PCR fragment. We detected a total of four polymorphisms, three within the 5 0 -regulatory region (À938C/A, À758T insertion and À42C/T) and one in exon 2 (21A/G) of the BCL-2 gene. Presumed alterations in the transcription factor binding sites owing to the 5 0 -regulatory region sequence variants were predicted using a web-based program (http://www.gene-regulation.com). 22 
Genotyping
We genotyped three (À938C/A and À42A/G within the promoter region and 21C/T within exon 2) of the four SNPs within the screening panel; however, the À758T insertion was not genotyped owing to difficulties encountered in genotyping within a poly-T tract. Genotyping of the three BCL-2 polymorphisms were performed using Pyrosequencing (PSQ 96 MAt) in the previously described sub-population samples. Four primer sequences were designed using Oligo 6.0t software to amplify two PCR fragments. The first fragment, involving 220 bp, included the À42C/T and 21A/G SNPs, was amplified by PCR using the following primers: a forward biotin-labelled primer, 5 0 -b-ACA CCC CCT CGT CCA AGA-3 0 ; and an unlabelled reverse primer, 5
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pyrosequencing primers were as follows: 5 0 -GCC AAC GGC ACC TCT-3 0 for the Y or C/T SNP; and 5 0 -TCA CTA TCT CCC GGT TAT-3 0 for the R or A/G SNP. A second fragment, comprising 210 bp, included the À938C/A SNP, was amplified and genotyped using the following primers: an unlabelled forward primer, 5 0 -GCA TTT GCT GTT CGG AGT T-3 0 ; a biotin-labelled reverse primer, 5 0 -b-CTA TCC ACG GGA CCG CTT C-3 0 ; and a sequencing primer, 5 0 -GGC TCC TTC ATC GTC-3 0 . Genotyping was carried out on the PSQ 96 Pyrosequencer according to the PSQ 96 MAt user manual and previously described standard protocol. 23, 24 The pyrogram of each sample was analysed individually in order to determine the genotypes. All genomic DNA samples were subjected to repeat genotyping, resulting in 100% concordance among replicate-blinded samples.
Statistical analysis
Differences in demographic and patient characteristics between cases and control were tested using the w 2 test for heterogeneity for categorical variables and the Wilcoxon rank-sum test for categorical and continuous variables, respectively. BCL-2 genotype and allele frequencies were calculated for African Americans, Jamaicans, European Americans and all sub-populations combined, stratified by case-control status. Differences in the allele and genotype frequencies among the three clinical populations and between patients and controls within each ethnic group were examined using the w 2 test for heterogeneity. Hardy-Weinberg equilibrium was evaluated in each group using a w 2 test for heterogeneity. BCL-2 haplotypes were estimated from the marker genotypes by a maximum likelihood ratio (LR) method using the CHAPLIN software, 25 which provides a LR statistic for testing the null hypothesis that there is no difference in the distribution of BCL-2 haplotypes between cases and controls.
Logistic regression models were used to estimate the odds ratio (OR) and 95% confidence interval (CI) for the association between prostate cancer risk and BCL-2 genotypes and haplotypes, adjusting for potential confounders (i.e., age at the time of diagnosis for case subjects and at the time of ascertainment for controls), using the homozygous wild-type genotype as the reference group. In order to assess whether ethnicity modified the association between genotype and the risk of developing prostate cancer, we stratified by ethnic group (i.e., European-American, African-American and Jamaican). Descriptive statistics and logistic regression analysis was performed using SAS version 6.91 (SAS Institute Inc., Cary, NC, USA) and a significance level of o0.05.
Results
Germline variants detected in the BCL-2 transcription regulatory and coding regions Four SNPs were identified in the BCL-2 transcription regulatory and coding regions, as shown in Table 3 and Figure 1 . Two of the polymorphisms observed were novel, namely À758T insertion and 21A/G; however, the À938C/A (rs2279115) and À42C/T (rs1801018) SNPs were identified previously, as reported in the dbSNP website database. Alterations in the putative transcription factor binding sites and amino-acid sequences owing to the SNPs are also depicted in Table 3 .
Frequency of BCL-2 genotypes and haplotypes
The distribution of BCL-2 genotypes and haplotypes among clinical sub-populations and all subjects combined are detailed in Table 4 . For each sub-population, all genotypes were in Hardy-Weinberg equilibrium (Po0.05; for all genotypes). Among all subjects combined, the frequencies of the hetero-/homozygous BCL-2 genotypes were fairly common (X15%). There was no significant difference in the BCL-2 allelic frequencies between African-American and Jamaican controls for each SNP. However, the BCL-2 À938A and 21G alleles were approximately 1.9-to 3.2-fold higher among European Americans relative to African Americans Germline BCL-2 sequence variants LR Kidd et al.
(P ¼ 0.005). On the other hand, the À42T allele was more prevalent among men of African descent (P ¼ 0.01) when compared to European-American men. Four common BCL-2 haplotypes designated as CCA, ACA, ACG and CTA represent over 97% of the chromosomes observed among all controls, as depicted in Table 4 . We observed differences in the distribution of BCL-2 haplotype frequencies among the controls of the three ethnic groups. For instance, the common CCA haplotype was approximately 1.5-fold more prevalent among controls of African descent when compared to European-American controls (66.2 vs 44.6%). Notably, the CTA haplotype was extremely rare among European-American controls, relative to men of African descent (2.0 vs 8.0-10.3%). On the other hand, we did not observe any differences in the frequencies of CCG and ACA haplotypes among controls for all three ethnic groups.
Association between prostate cancer and BCL-2 genotypes and haplotypes
The association between specific genetic alterations in the BCL-2 gene (À938, À42 and 21) and the risk of developing prostate cancer was examined using logistic regression analysis, as summarized in Table 5 . As a relatively small proportion of controls were homozygous variant for all BCL-2 alleles, we combined the heterozygous and homozygous genotypes to represent the variant genotype. All associations are reported in reference to the wild-type genotype. We did not observe any significant associations between the variant BCL-2 genotypes and prostate cancer susceptibility among the three combined clinical populations of African-American, Jamaican and European-American. However, we demonstrated a 70% decrease in prostate cancer risk among European Americans who possessed two À938A BCL-2 alleles (OR ¼ 0.30; 95% CI ¼ 0.13-0.70), when compared to those with the wild-type genotype, after adjusting for age. Similarly, Jamaican men who had at least one 21G allele had a 63% reduction in the risk of developing prostate cancer (OR ¼ 0.37; 95% CI ¼ 0.15-0.93).
Given the single SNP associations with prostate cancer risk observed for À938C/A in European Americans and 21A/G in Jamaicans, we were particularly interested in performing the haplotype analysis. The global LR test using all subjects combined revealed that BCL-2 haplotype frequencies differed significantly between prostate cancer cases and controls (P ¼ 0.009) ( Table 6 ). We also evaluated the effects of individual haplotypes for all the (41) 195 (37) 45 (37) 101 (36) 27 (34) 29 (31) 44 (53) 55 (48) AA 18 (6) 52 (10) 8 (6) 15 (5) 2 (3) 6 (6) 8 (10) 30 (26) À42C/T CC 256 (89) 461 (85) 115 (88) 240 (82) 46 (77) 77 (79) 93 (99) 117 (96) CT 30 (11) 76 (14) 15 (12) 49 (17) 14 (23) 18 (19) 1 (1) (71) 371 (73) 104 (81) 223 (83) 73 (91) 73 (79) 34 (39) 47 (40) AG 74 (25) 110 (22) 23 (18) 42 (15) 7 (9) 18 (20) 44 (49) 50 (43) GG 12 (4) 28 (5) 1 (1) 6 (2) -1 (1) 11 (12) 21 (17) BCL-2 haplotype Germline BCL-2 sequence variants LR Kidd et al.
cases combined and separately for the three ethnic groups. Haplotype CTA was observed more in the controls than among the cases (7.9 compared to 4.9%) and was significantly associated with decreased risk for prostate cancer (OR ¼ 0.61; 95% CI ¼ 0.39-0.93; P ¼ 0.01). We note that this protective haplotype was rare in European Americans (o2.0%). In the subset analyses, we observed no differences in haplotype frequencies between cases and controls for African Americans and Jamaicans ( 
Discussion
Bcl-2 is an antiapoptotic mediator that has been implicated in the pathogenesis of epithelial malignancies, including prostate cancer. 19, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Overexpression of the BCL-2 gene may predispose dysplastic epithelium to genetic instability, which may lead to neoplasia and the invasive phenotype. To our knowledge, there are no published reports on the relationship between genetic alterations in the antiapoptotic-related gene, namely BCL-2, and prostate cancer risk. Thus, we evaluated the association between genetic alterations within the noncoding and coding regions of the BCL-2 gene and prostate cancer susceptibility among men of African and European descent. We examined two previously identified SNPs within the transcription regulatory region (À938C/A and À42C/T) and one novel SNP within the coding region (21A/G) of the BCL-2 gene. Among European Americans, we revealed a 70% decrease in prostate cancer risk among men with the BCL-2 À938AA genotype. Similarly, Jamaican men who possessed the BCL-2 21G allele were approximately 60% less likely to develop prostate cancer relative to those who had the referent genotype.
Preliminary prediction of the elimination of the Sp1 transcription factor binding site owing to a À938C/A polymorphism within the regulatory region of the BCL-2 gene enabled us to propose a post hoc explanation for reduced prostate cancer susceptibility among EuropeanAmerican men who possessed the BCL-2 À938A allele. Briefly, we speculate that elimination of the Sp1 Haplotype sequence at the BCL-2 gene cluster consists of À938C/A, À42C/T and 21A/G. b OR and corresponding 95% CI for BCL-2 haplotypes and prostate cancer were determined using univariate logistic regression controlling for age at diagnosis. Global test LR P-values derived from testing haplotypes frequencies in case populations vs controls.
transcription factor binding site at position À938, owing to a C/A polymorphism, may result in a downregulation of bcl-2 mRNA transcript levels, a decrease in cellular levels of bcl-2 protein, unregulated programmed cell death, reduced longevity of transformed cells and a subsequent decrease in the risk of developing prostate cancer ( Figure 2 ). However, site-directed mutagenesis studies are needed to confirm the aforementioned hypothesis.
To our knowledge, there are no published reports on whether elimination of the Sp1 transcription factor binding site at 938 bp upstream of the transcription start site regulates bcl-2 mRNA expression. However, both Sp1 sites and CRE are major positive regulators of BCL-2 P1 transcription activity. 37, 38 In fact, deletion of Sp1 and CRE sites localized between base pairs À1525 and À1640 using transient transfection assays resulted in the repression of bcl-2 promoter activity in b-cells. 38 Moreover, mutation of the 3 0 Sp1 site at À1332 had a small effect on BCL-2 P1 activity; however, mutations within the 5 0 Sp1 or CRE site at positions À1578 and À1537, respectively, resulted in a substantial decrease in transcription activity. When a mutated CRE site was combined with one or more mutated Sp1 site(s) (i.e., 5 0 Sp1 alone or 5 0 and 3 0 Sp1 combined), low or undetectable levels of promoter activity were observed. 38 In the same study, the investigators demonstrated that CRE and Sp1 may mediate the upregulation of bcl-2 activity through the NF-kB pathway. These findings suggest that elimination of a single 3 0 Sp1 site at À938, owing to a C/ A nucleotide substitution, may have a small effect on bcl-2 transcription levels. However, functional studies are needed to determine whether 3 0 elimination of the SP1 site at À938 will result in a decrease in bcl-2 mRNA levels and its potential role in apoptosis and prostate tumorigenesis.
The role of apoptosis in prostate tumorigenesis, including its regulation by members of the Bcl-2 family, is controversial and complex. Based on the findings of the current study, we hypothesize that the higher risk of developing prostate cancer among European-American men who possess the À938 C/C BCL-2 genotype (i.e., the proposed high BCL-2 expression genotype) may be partially attributed to suppressed apoptotic activity. Consistent with our hypothesis, Oltvai et al. 6 revealed that high expression of bcl-2 combined with low expression of bax, a proapoptotic factor, was associated with increased transition from normal prostate epithelium to neoplasia, presumably owing to a downregulation in apoptosis, escape of transformed cells from programmed cell death, increased cell accumulation and an increase in tumour formation.
Alternatively, other investigators speculate that overexpression of bcl-2 may serve as a survival factor that attempts to counteract the high rate of apoptotic activity and a high level of proapoptosis-related proteins (e.g., bax). This is partially supported by the findings of Xie et al. 39 who observed increased protein expression of bcl-2 in high-grade prostatic intraepithelial neoplasia (HGPIN) lesions, a candidate precursor of prostate cancer, in Noble rats relative to low-grade prostatic intraepithelial neoplasia (LGPIN) samples, for instance, the high apoptotic index in highly proliferative HGPIN lesions. Other investigators also observed an overexpression of bcl-2 in HGPIN lesions compared to LGPIN samples in human prostate samples, suggesting a role for increased bcl-2 in the progression of prostate cancer in humans. Xie et al. 39 speculated that the high apoptotic index, partially regulated by high bax expression, may facilitate removal of DNA damage or unnecessary cells, resulting in a higher rate of cell turnover and proliferative activity. In contrast, the increased expression of bcl-2 in HGPIN, presumably during the early development of prostatic neoplasms, may help to counteract apoptosis and protect cells from programmed cell death. 39 Similarly, increased bcl-2 expression has been reported in colorectal adenomas, cervical intraepithelial neoplasia and other precancerous lesions, suggesting that bcl-2 plays an oncogenic role during the early stages of carcinogenesis in cells other than prostate epithelial cells. 17, 33, 40, 41 We are aware of various limitations in the current study. For instance, we did not consider the interaction between variations in the BCL-2 gene and other targets that may regulate or modulate apoptosis, including: (1) oncogenes/tumour suppressor genes such as p53, myc, ras, abl, raf, jun and the bcl-2 family (i.e., other prosurvival and prodeath); (2) hormones (i.e., androgen/androgen receptor), cytokines and growth factor/ growth factor receptors (e.g., tumour necrosis factor-á/ Fas and tumour growth factor-b (TGF-b)/TGF-b receptor), endothelial growth factor/endothelial growth factor receptor and (3) extracellular matrix regulators/cell adhesion molecules. Based on in vitro studies, when bax is overexpressed relative to bcl-2, accelerated programmed cell death predominates, and bax represses the antiapoptotic activity of bcl-2, presumably owing to homo-and hetero-dimerization, respectively. These findings suggest that the bax/bcl-2 ratio is a critical determinant for the induction or inhibition of apoptosis. 6, 42 As a consequence, future studies should consider the impact of genetic variations in a panel of apoptosisregulating genes in the development and progression of prostate cancer. Figure 2 Hypothesized mechanism for interaction between the BCL-2 À938C/A polymorphism and prostate cancer susceptibility. European-American men who possess the proposed transcriptionally inactive BCL-2 À938A allele may have reduced local BCL-2 levels, resulting in suppressed BCL-2-mediated inhibition of apoptosis, enhanced programmed cell death, reduced longevity of transformed cells and subsequent decreased risk of developing prostate cancer.
In addition, based on the prevalence of the hetero-or homozygous variant À938CA/AA genotypes within our control population and sample size, we had a statistical power of 80% to observe risk-related ORo0.66 comparing individuals who had at least one variant allele (À938A) to the referent genotype. Unfortunately, in our stratified analysis, we did not have sufficient statistical power to assess the relationship between prostate cancer susceptibility and genetic alteration within the BCL-2 gene stratified by racial/ethnic group. However, the significant protective effect of the À938AA BCL-2 genotype against prostate cancer among European Americans warrants further consideration in larger observational studies. In addition, population stratification that may also influence our observed risk estimates in the combined analyses; however, this would be less of an issue in our analyses stratified according to ethnicity.
In spite of the aforementioned study limitations, our study demonstrating the protective effects of the À938AA BCL-2 genotype against prostate cancer among European-American men may have some implications for therapeutic regimens against prostate cancer. In particular, therapeutic agents that lead to the degradation of bcl-2 mRNA and subsequent inhibition of the bcl-2 gene product, such as bcl-2 antisense oligonucleotides, may reduce susceptibility to prostate cancer, particularly among men express high levels of BCL-2.
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In summary, our findings suggest that the BCL-2 À938C/A polymorphism may be associated with a decrease in susceptibility to prostate cancer, particularly among European-American men. However, functional assays are necessary in order to determine whether the deletion of the putative Sp1 transcription factor binding site at this location in the BCL gene promoter has an impact on bcl-2 mRNA transcription, apoptotic index and ultimately prostate tumorigenesis. These findings, combined with other genes that regulate apoptosis, may partially explain ethnic differences in prostate cancer incidence. It is our hope that our findings will help to guide more rationale approaches in the development of efficacious therapeutic regimens for prostate cancer, such as therapies that block antiapoptotic gene targets (e.g., BCL-2).
